一、对外投资概述 证券代码：300404 证券简称：博济医药 公告编号：2025-054 博济医药科技股份有限公司 关于南阳中医药基金相关事项变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2022 年 1 月 26 日，博济医药科技股份有限公司（以下简称"公司"）召开 第四届董事会第十七次会议，审议通过了《关于全资子公司参与投资南阳中医药 基金的议案》，同意公司全资子西藏博济投资管理有限公司（以下简称"博济投 资"）作为有限合伙人参与投资南阳现代中医药私募投资基金（有限合伙）（以下 简称"合伙企业"），具体内容详见公司于 2022 年 1 月 27 日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露的《关于全资子公司参与投资南阳中医药基 金的公告》（公告编号：2022-011）。合伙企业总规模为人民币 100,000 万元，博 济投资以自有资金出资 6,000 万元，占总出资额的 6.00%。合伙企业的合伙人及 出资情况如下： | 序号 | 合伙人 | 出资额 | 出资比 | 合伙人类别 | 出资 | | --- | - ...

特别提示： 1、本次归属限制性股票的激励对象合计 22 名，归属限制性股票数量合计 1, 140,000 股，占目前公司总股本的 0.2973%； 2、本次归属股份的上市流通日：2025 年 7 月 7 日。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第五届董事会第十三次会议和第五届监事会第十二次会议，审议通过了《关于 公司 2024 年限制性股票激励计划第一个归属期归属条件成就的议案》，董事会 认为公司 2024 年限制性股票激励计划（以下简称"本激励计划"）第一个归属 期归属条件已成就。近日，公司办理了第一个归属期归属股份的登记工作。现将 有关情况公告如下： 一、公司 2024 年限制性股票激励计划概述及已履行的相关程序 1、 2024 年 3 月 19 日，公司第五届董事会第六次会议审议通过了《关于公 司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2024 年 限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会 办理 2024 年限制性股票激励计划相关事宜的议案》等议案。同日，公司第五届 监事会第六次会议审议通过 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

近日，博济医药科技股份有限公司（以下简称"公司"）全资子公司杏林中 医药科技（广州）有限公司获得国家知识产权局颁发的两项发明专利证书，具体 情况如下： 一、专利基本情况 证券代码：300404 证券简称：博济医药 公告编号：2025-052 博济医药科技股份有限公司 关于全资子公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 序号 | 发明名称 | 专利权人 | 证书号 | 专利号 | | 专利申请日 | | | 授权公告日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种高生物利用 度的西红花酸钠 纳米复杂制剂、 | 杏林中医药 科技（广州） | 第8034214号 | | | | | | 年 06 日 27 | | | | | | ZL 2024 1 | 2024 | 年 | 01 | 2025 | | | | | | | 0078631.9 | 月 | 18 | 日 | 月 | | | | 制备方法、药物 | 有限公司 | | | ...

博济医药科技股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）近日接到公司控股股东王 廷春先生的通知，获悉王廷春先生将其所持有的公司部分股份在国泰海通证券股 份有限公司（以下简称"国泰海通"，原名"国泰君安证券股份有限公司"）办理 了股份质押展期的手续，具体事项如下： 证券代码：300404 证券简称：博济医药 公告编号：2025-051 注 1：王廷春先生、赵伶俐女士所持限售股份性质为高管锁定股，故上表中的"已质押股份限售和冻 结数量"及"未质押股份限售和冻结数量"均系高管锁定股。 一、股东股份质押展期的基本情况 | 股东名 | 是否为第一 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押开始 | | 原质押 | | 展期后 | | 质权 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股 ...

Group 1 - The Chongqing Liangjiang New Area has gathered multiple pilot test platforms represented by companies like Boji Pharmaceutical, Boteng Pharmaceutical, and Huaguan Biotechnology, providing "one-stop" services for the acceleration of scientific research results into industrialization [1][3] - Pilot test platforms are comprehensive support platforms that facilitate the transition of research results from laboratory development to large-scale industrial production, playing a key role in the commercialization of innovative outcomes [3] - The Ministry of Industry and Information Technology and the National Development and Reform Commission aim to cultivate over 20 pilot test capability construction platforms by 2027, serving more than 200 companies and incubating over 400 products [3] Group 2 - Boji Pharmaceutical's subsidiary, Chongqing Boji Pharmaceutical Co., Ltd., focuses on high-tech barrier and high R&D cost complex injection drug development and production, with a platform that includes R&D laboratories, quality testing centers, and sterile injection production workshops [4] - The company has incubated 8 pharmaceutical enterprises to date and aims to assist more clients in completing multiple major complex injection drugs for the first time in China, as well as achieving international registration and market expansion [4] - Boteng Pharmaceutical, also located in the Water and Soil New City, provides one-stop service solutions for small molecule drugs, peptides, oligonucleotide drugs, protein and conjugate drugs, and cell and gene therapy drugs, covering the entire lifecycle from preclinical research to drug commercialization [4] Group 3 - The Liangjiang New Area is recognized as a core area for the development of the life and health industry, currently hosting 25 various platforms related to technical services, administrative regulation, industrial incubation, scientific innovation, and clinical services [5] - The area is continuously optimizing its industrial ecosystem and improving its service system to inject momentum into the collaborative innovation development of the biopharmaceutical industry chain [5]

博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 的第五届董事会第十四次会议和第五届监事第十三次会议，审议通过了《关于公 司 2022 年股票期权激励计划第三个行权期行权条件成就的议案》，公司《2022 年股票期权激励计划（草案）》（以下简称"本激励计划"）设定的股票期权第 三个行权期行权条件已成就，同意公司根据 2022 年第二次临时股东大会的授权， 按照本激励计划的相关规定办理第三个行权期的相关行权事宜，具体内容详见公 司 2025 年 4 月 26 日披露于巨潮资讯网的《关于公司 2022 年股票期权激励计划 第三个行权期行权条件成就的公告》（公告编号：2025-027）。 证券代码：300404 证券简称：博济医药 公告编号：2025-050 博济医药科技股份有限公司 关于公司 2022 年股票期权激励计划 第三个行权期采用自主行权的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据本激励计划规定，本激励计划授予的股票期权分三次行权，可行权比例 分别为股票期权授予总量的 30%、30%和 40%。本次行权 ...

解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300404 证券简称：博济医药 公告编号：2025-049 博济医药科技股份有限公司 关于公司 2023 年限制性股票激励计划首次授予部分 第二个解除限售期及预留授予部分第一个解除限售期 1、本次符合 2023 年限制性股票激励计划第一类限制性股票解除限售的激 励对象人数合计 4 人，可解除限售的股票数量合计 230,000 股，占目前公司总股 本的 0.0600%。其中，符合首次授予部分第二个解除限售期解除限售条件的激 励对象人数为 3 人，可解除限售的股票数量为 200,000 股，占目前公司总股本的 0.0522%；符合预留授予部分第一个解除限售期解除限售条件的激励对象人数为 1 人，可解除限售的股票数量为 30,000 股，占目前公司总股本的 0.0078%。 2、本次限售股份上市流通日为：2025 年 6 月 16 日。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第五届董事会第十三次会议和第五届监事会第十 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-048 博济医药科技股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 博济医药科技股份有限公司董事会 2025 年 6 月 12 日 1 特别提示： 1、本次注销 2022 年股票期权激励计划中到期未行权的部分股票期权数量 为 222,640 份，涉及人数为 21 人。 2、公司已在中国证券登记结算有限责任公司深圳分公司完成了本次股票期 权的注销手续。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日召开 第五届董事会第十四次会议和第五届监事会第十三次会议，审议通过了《关于注 销部分股票期权的议案》。根据公司《2022 年股票期权激励计划（草案）》等 有关规定，公司 2022 年股票期权激励计划的第二个行权期已届满，公司部分激 励对象在第二个行权期的行权额度未能全部行权，公司注销其到期未行权的股票 期权 222,640 份。具体内容详见公司于 2025 年 6 月 10 日在巨潮资讯网上披露的 《关于注销部分股票期 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-047 博济医药科技股份有限公司 特此公告。 更正公告 博济医药科技股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 6 月 10 日 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 6 月 7 日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《关于注销部分股票期权的公告》 （公告编号：2025-046）、《北京市康达（广州）律师事务所关于公司 2022 年股票 期权激励计划注销部分股票期权的法律意见书》。经事后审查发现，上述公告中 涉及的第二个行权期到期未行权的股票期权数量有误，现补充更正并说明如下： 将原公告中"公司部分激励对象在第二个行权期的行权额度未能全部行权， 同意公司注销其到期未行权的股票期权 235,240 份。"更正为"公司部分激励对 象在第二个行权期的行权额度未能全部行权，同意公司注销其到期未行权的股票 期权 222,640 份。" 除上述更正内容之外，原公告其他内容不变。对于本次更正给投资者带来的 不便，公 ...